Fiche publication
Date publication
octobre 2022
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOUSTANI Jihane
Tous les auteurs :
Boustani J, Créhange G
Lien Pubmed
Résumé
For non-operable, localized esophageal cancer, definitive concurrent chemoradiotherapy is the standard treatment. Currently, the radiation dose recommended is 50 to 50,4Gy. However, the optimal radiation dose remains controversial. Many studies have demonstrated that locoregional failure remains a common failure pattern, most likely to occur within the original gross tumor volume. Several retrospective studies have indicated that higher radiation dose may improve local control and survival while others failed to demonstrate improved oucomes. In three randomized trials (INT0123, ARTDECO, and CONCORDE), dose escalation did not improve locoregional control nor survival, establishing 50Gy as the standard chemoradiation dose for patients who will not undergo surgery. Here, we reviewed the results of dose escalation in the literature in the neoadjuvant and definitive settings.
Mots clés
Cancer de l’œsophage, Chemoradiation, Chimioradiothérapie, Contrôle locorégional, Dose-escalation, Escalade de dose, Esophageal cancer, Locoregional control
Référence
Cancer Radiother. 2022 10;26(6-7):884-889
